MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cam4.1388

Медицинская библиотека · Cancer medicine · 2018

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.

Vacirca Jeffrey L, Chan Arlene, Mezei Klára, Adoo Clarence S, Pápai Zsuzsanna, McGregor Kimberly, Okera Meena, Horváth Zsolt, Landherr László, Hanslik Jerzy, Hager Steven J, Ibrahim Emad N, Rostom Makharadze, Bhat Gajanan, Choi Mi Rim, Reddy Guru, Tedesco Karen L, Agajanian Richy, Láng István, Schwartzberg Lee S

Сравнительное исследованиеКонтролируемое клиническое исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

This randomized, open-label, active-controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long-acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficacy endpoint was duration of severe neutropenia (DSN) during the first cycle of treatment. Patients who were candidates for adjuvant/neoadjuvant TC chemotherapy were eligible for participation. TC was administered on Day 1, followed by 45, 135, or 270 μg/kg Rolontis or 6 mg pegfilgrastim on Day 2. Complete blood counts were monitored daily when the absolute neutrophil count (ANC) fell to <1.5 × 109 /L. Up to four cycles of TC were investigated. The difference in DSN (time from ANC <0.5 × 109 /L to ANC recovery ≥2.0 × 109 /L) between the Rolontis and pegfilgrastim groups was -0.28 days (confidence interval [CI]: -0.56, -0.06) at 270 μg/kg, 0.14 days (CI: -0.28, 0.64) at 135 μg/kg, and 0.72 days (CI: 0.19, 1.27) at 45 μg/kg. Noninferiority to pegfilgrastim was demonstrated at 135 μg/kg (P = 0.002) and 270 μg/kg (P < .001), with superiority demonstrated at 270 μg/kg (0.03 days; P = 0.023). The most common treatment-related adverse events (AEs) were bone pain, myalgia, arthralgia, back pain, and elevated white blood cell counts, with similar incidences across groups. All doses of Rolontis were well tolerated, and no new or significant treatment-related toxicities were observed. In Cycle 1, Rolontis demonstrated noninferiority at the 135 μg/kg dose and statistical superiority in DSN at the 270 μg/kg dose when compared to pegfilgrastim.

Для цитирования: Vacirca Jeffrey L, Chan Arlene, Mezei Klára, Adoo Clarence S, Pápai Zsuzsanna, McGregor Kimberly, Okera Meena, Horváth Zsolt, Landherr László, Hanslik Jerzy, Hager Steven J, Ibrahim Emad N, Rostom Makharadze, Bhat Gajanan, Choi Mi Rim, Reddy Guru, Tedesco Karen L, Agajanian Richy, Láng István, Schwartzberg Lee S. An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.. Cancer medicine. 2018. DOI: 10.1002/cam4.1388.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.